spacer
home > ebr > spring 2007 > life after death
PUBLICATIONS
European Biopharmaceutical Review

Life after Death

Ann-Christin Malmborg Hager and Christina Furebring at Alligator Bioscience AB and Philippe Stas at AlgoNomics look at a growing trend for resuscitating abandoned clinical trials

Developing pharmaceuticals is a risky business, involving enormous costs. While pharmaceutical companies invest heavily in those molecules they believe in, a failure during the development process can be very damaging. According to several reports, only 10 per cent of drug candidates entering the preclinical phase will reach the market; what happens to the rest? Do the remaining 90 per cent that do not make it to the market forever inhabit the drug companies’wastepaper baskets? This article discusses a project that is put back on track after a failure in Phase I.

THE CHIPS PROTEIN

The drug candidate in question was chemotaxis inhibitory protein of Staphylococcus aureus (CHIPS) (1). The protein was discovered by the research group of Jos van Strijp, Professor of Microbiology at the Eijkman Winkler Institute in Utrecht, the Netherlands.

When bacteria enter the human body they are surrounded by human proteins. One of these proteins is C5a, a component of the complement system. C5a binds to the C5a receptor (C5aR), which is found on the surface of, for example, neutrophils, a very important cell type in the innate immune system. This activates the neutrophils, while stimulating chemotaxis so that more inflammatory cells are recruited to the site of infection.

To protect themselves, bacteria – in this case Staphylococci – develop mechanisms to prevent themselves from being destroyed by the recruited neutrophils (2). One mechanism used by Staphylococci is the production of a 14kD protein (the CHIPS protein) that downregulates the ability of C5aR to bind its ligands, by blocking the binding site of C5a. This blocks neutrophil chemotaxis.

The plan was to use CHIPS, with its anti-inflammatory effects, as a drug, preventing the progression of neutrophil-mediated inflammation that gives rise to and aggravates disease symptoms. In indications involving acute cases of inflammation, the effects of CHIPS could be beneficial, and at present there are no drugs on the market for such indications. The mechanism of CHIPS´ antiinflammatory ability is schematically outlined in Figure 1.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Dr Ann-Christin Malmborg Hager is Vice President of Business Development at Alligator Bioscience AB and holds a PhD in Immunotechnology from Lund University. She is one of the inventors of the Alligator proprietary technology, FIND®, and a founder of the company. Prior to joining Alligator, Ann-Christin held a position at Lund University and held a post-doctoral position at the University of California, Davis.

Dr Christina Furebring is Vice President of Research and Development at Alligator Bioscience AB, and holds a PhD in Immunotechnology from Lund University. She is also one of the inventors of the Alligator proprietary technology, FIND®, and a founder of the company. Christina previously held a position at Lund University and held a post-doctoral position at the University of Utrecht, the Netherlands.

Philippe Stas, Chief Operating Officer at AlgoNomics since 1990, has been involved in antibody engineering, immunology and bioinformatics research at the University of Brussels. After working as IT Manager for PE Genscope, he joined the team that created AlgoNomics in 1999. Philippe is president of the Belgian Association for Bioindustries.

spacer
Dr Ann-Christin Malmborg Hager
spacer
spacer
spacer
Dr Christina Furebring
spacer
spacer
spacer
Philippe Stas
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

3rd African Regulatory Conference (ARC)

3-4 May 2012, Accra, Ghana

The African Regulatory Conference offers the opportunity for key stakeholders active on the continent, including representatives from Ministry of Health, local and multinational pharmaceutical companies, to meet to exchange views, discuss topics of interest and identify focus areas for ongoing efforts to increase patient access to new and improved medicines.
More info >>

 
News and Press Releases

APTAR PHARMA’S PRESERVATIVE-FREE MULTIDOSE DISPENSER OSD CHOSEN FOR THE FIRST TIME FOR AN EYE CARE PRODUCT

Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser (OSD) has found its first application for the treatment of dry eye with the launch of VISMED® MULTI. Aptar Pharma has worked closely with the Swiss-German based Eye Care specialist TRB Chemedica for improving patient safety, achieving dosing accuracy and maintaining product stability on the ophthalmic spray device.
More info >>

 

 

Buy Atrovent Online no prescription Buy Symbicort Online no prescription Buy Flovent Online no prescription Buy Flonase Online no prescription Buy Rhinocort Online no prescription Buy Allegra Online no prescription Buy Advair Online no prescription Buy Combivent Online no prescription Buy Astelin Online no prescription Buy Spiriva Online no prescription Buy Ventolin Online no prescription
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement
.